Navigation Links
Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
Date:10/25/2010

f the vaccine efficacy in potential future pivotal Phase III trials.

"With this successfully conducted clinical trial Intercell further strengthens its leading position in the field of hospital acquired infections. As Pseudomonas is known as a major contributor to death in the complex patient population studied in the present trial we are pleased to see reduced mortality in the vaccination groups. We are looking forward to further evaluating the underlying mechanisms and the future potential development options for this vaccine candidate," comments Thomas Lingelbach, Chief Operating Officer of Intercell AG.

Novartis Vaccines and Diagnostics have certain option rights with respect to this vaccine candidate and will review the data to determine next steps together with Intercell.

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
2. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
3. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
4. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
5. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
8. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
9. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Cardium Therapeutics,(Amex: CXM ) and its ... findings from a preclinical study, demonstrating a ... (cooling) for the potential,treatment of acute myocardial ... BioMed Central (BMC) Cardiovascular Disorders (2008, 8:7, ...
... - New Approach to Targeting the Tumor ... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... the extracellular matrix, today,announced new pre-clinical findings ... the American Association for Cancer Research (AACR) ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 2Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 3Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 4
(Date:7/10/2014)... According to a new market research ... Airborne, Naval), Application (Software Defined Radios, SATCOM, Encryption, ... America, Asia-Pacific, Europe, the Middle East & ROW) ... the market is estimated to be $30.15 billion ... CAGR of 5.56% to reach $39.52 billion by ...
(Date:7/10/2014)... 10, 2014 Best Drug ... that having family close by during a stay ... whether or not the process is successful, has ... website at http://www.bestdrugrehabilitation.com/success-stories/ . , The new ... testimonials from several Best Drug Rehabilitation graduates who ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
(Date:7/10/2014)... not nurture, may play the bigger role in the ... "As is the case in humans, genes matter ... William Hopkins of the Yerkes National Primate Research Center ... journal Current Biology . The findings might ... humans, Hopkins, team said. According to the researchers, ...
(Date:7/10/2014)... who are sensitive to light or noise after a ... as anxiety and depression, a new study says. ... teens experience after concussion may help in planning for ... to return to play and what accommodations are needed ... and Dong Han, of the University of Kentucky in ...
Breaking Medicine News(10 mins):Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Some Teens May Face Emotional Problems After Concussion 2
... , , IRVING, Texas, ... (OTC Bulletin Board: RBCL), a provider of proprietary nutritional supplements and ... the ClearPay System, a compensation plan that rewards the company,s independent ... The ClearPay System is the ...
... , , , ... with painful conditions, September is a time for their true ... communication, National Pain Awareness Month allows people with painful conditions ... fight their pain. , , Fibromyalgia has ...
... of infections on campus already increasing rapidly; could ... , TUESDAY, Sept. 8 (HealthDay News) -- Erica Goldfine, ... to school this semester to find a new item ... cheating: emergency preparedness procedures for the H1N1 swine flu. ...
... , CLAREMONT, Calif., Sept. 8 ... that personalized medicine will have on life science companies, physicians, patients, ... "Personalized medicine will change how medicine is delivered," said Diana Bartlett, ... longer one size fits all. Your therapy may be different from ...
... Ala., Sept. 8 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ... two upcoming investor conferences. , , ... to present a corporate summary at the Rodman & Renshaw Annual ... Eastern Time. The conference will be held September 9-11, 2009 in ...
... , , JACKSONVILLE, Fla., Sept. 8 ... to getting the job done. Yet, new research reveals that as they ... to perform everyday activities at home and on the job. , ... are concerned that their vision is getting worse as they age, and ...
Cached Medicine News:Health News:RBC Life Sciences Unveils the ClearPay System - the Industry's First Balancing Compensation Plan That Pays Quickly and Abundantly 2Health News:RBC Life Sciences Unveils the ClearPay System - the Industry's First Balancing Compensation Plan That Pays Quickly and Abundantly 3Health News:Know Fibro Initiative Commemorates National Pain Awareness Month 2Health News:Know Fibro Initiative Commemorates National Pain Awareness Month 3Health News:Colleges Move to Limit Swine Flu's Spread 2Health News:Colleges Move to Limit Swine Flu's Spread 3Health News:Colleges Move to Limit Swine Flu's Spread 4Health News:KGI to Host Public Discussion on Personalized Medicine 2Health News:BioCryst Executives to Present at Two Investor Conferences 2Health News:Working Moms' Vision Not 'Near' Perfect 2Health News:Working Moms' Vision Not 'Near' Perfect 3
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: